# Asahi Kasei Corporate Venture Capital

> Asahi Kasei Corporate Venture Capital is a VC fund backing Biotechnology. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 12
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.asahikaseiventures.com/

Asahi Kasei Corporate Venture Capital is an investment firm that focused on primary sectors of homes, materials, and healthcare. The firm is focused on investing in innovative global firms in areas of strategic importance to Asahi Kasei. The company mission to create new long-term business opportunities for Asahi Kasei.Asahi Kasei CorporateVenture Capital was founded in 2008 and is based in Tokyo with offices in Menlo Park and Boston Area.

## Contacts

5 contacts available for Asahi Kasei Corporate Venture Capital. Shizune tracks 3 team members at Asahi Kasei Corporate Venture Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/asahi-kasei-corporate-venture-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Health Care | 4 | 33% |
| Therapeutics | 4 | 33% |
| Wellness | 2 | 17% |
| Manufacturing | 2 | 17% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 42% |
| Series B | 3 | 25% |
| Series C | 3 | 25% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 58% |
| Canada | 2 | 17% |
| China | 1 | 8% |
| Japan | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Howard Kim | Managing Director | 0 | https://shizune.co/investors/profile/howard-kim-4aa5 |
| Steven Berger | Managing Director of New Business Development | 0 | https://shizune.co/investors/profile/steven-berger-470b |
| Takashi Morishita | General Manager | 4 | https://shizune.co/investors/profile/takashi-morishita |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| pH7 | pH7 is a cleantech firm that develops and implements methods for the sustainable extraction and refining of strategic metals, which are required for the transition to renewable energy. This pilot project will offer the industry a solution for the sustainable extraction of Platinum Group Metals from secondary and primary resources using green,biodegradable, and recyclable solvents rather than smelting methodologies. | $6.2M | Series B | Apr 13, 2026 |  |
| Glycomine | Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M | Series C | Apr 16, 2025 |  |
| Kins | Kins is a modern physical therapy for injury and chronic pain. | $7M | Series A | Jul 16, 2024 |  |
| Swing Therapeutics | Swing is creating the next generation of safe and effective digital therapeutics for people with chronic conditions. Our team of passionate scientists, clinicians, and technologists are partnering with some of the world’s top researchers to develop evidence-based transformative digital treatments. Swing’s solutions empower patients to regaincontrol of their illnesses. Together, we are helping people achieve improved health so that they can lead more joyful, vibrant lives. | $10.3M | Series A | Jun 16, 2022 |  |
| Koya Medical | Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy. | $26M | Series B | Feb 03, 2022 |  |
| Rege Nephro | Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. |  | Series A | Jan 31, 2022 |  |
| Aerobiotix | Aerobiotix is a privately held company specializing in the development and manufacture of proprietary environmental management devices for use in institutional healthcare, home health, and commercial settings. | $25M | Venture - Series Unknown | May 06, 2021 |  |
| Hazel Technologies | Hazel Technologies develops biotechnology for reducing waste in the agricultural supply chain. Their product development is funded in part by the United States Department of Agriculture (USDA) and their product performance has been validated by 3rd party academic research institutions such as Cornell University. The company provides USDA-funded1-MCP technology conditions the storage atmosphere to reduce respiration rate & increase resistance to ethylene.Hazel Technologies offers horticultural consulting services to growers and shippers, as well as develops new solutions to reduce food waste to improve the fresh produce supply chain. It also provides shelf-life extension technologies and services to combat the global food waste problem and improve profitability for its customers.Hazel Technologies was founded in 2015 and is headquartered in Chicago, Illinois, USA. | $70M | Series C | Apr 13, 2021 |  |
| Firework | Firework offers video commerce solutions built for websites, apps, and stores. They operate a storytelling platform intended to live stream videos directly on the website. The company's platform features in-video shopping, lead generation, and live streaming events and allows importing and editing videos, enabling brands to engage and converttheir website visitors. | $55M | Series A | Mar 24, 2021 |  |
| Dami&Xiaomi | Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information. | $1.5M | Series C | Nov 18, 2020 |  |

10 of 12 investments shown.

## Co-investors
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 2 deals together
- [Pangaea Ventures](https://shizune.co/investors/profile/pangaea-ventures) — VC Fund, 2 deals together
- [Rhapsody Venture Partners](https://shizune.co/investors/profile/rhapsody-venture-partners-llc) — VC Fund, 2 deals together
- [S2G Investments](https://shizune.co/investors/profile/s2g-ventures) — VC Fund, 2 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [3×5 Partners](https://shizune.co/investors/profile/3x5-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Asahi Kasei Corporate Venture Capital invest in?

Asahi Kasei Corporate Venture Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Asahi Kasei Corporate Venture Capital?

Public channels for Asahi Kasei Corporate Venture Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Asahi Kasei Corporate Venture Capital?

The team at Asahi Kasei Corporate Venture Capital includes Howard Kim (Managing Director), Steven Berger (Managing Director of New Business Development) and Takashi Morishita (General Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co